Shared Decision-Making in Obesity Care: Treatment Choices

Learn how shared decision-making helps patients and clinicians compare obesity treatments based on health goals, risks, preferences, cost, and access.

WEIGHT MANAGEMENTFOUNDATIONS & GENERAL EDUCATION

Sarina Helton, MSN, APRN, FNP-C, CAE-OM Founder, Optima Vida Healthcare

9/8/20268 min read

two white-and-pink flamingoes running on water

Shared Decision-Making in Obesity Treatment: Your Health, Goals, and Choices

Shared decision-making in obesity treatment is a collaborative process in which a patient and healthcare professional make treatment decisions together.
The clinician contributes medical evidence, clinical experience, and a safety assessment. The patient contributes something equally important: personal goals, preferences, previous experiences, financial realities, and what they are willing or unwilling to do.
Obesity treatment should not be something done to a patient. It should be developed with the patient.

Obesity Does Not Have One Correct Treatment

Obesity is a complex, chronic disease with multiple possible treatments, including:

Nutrition and behavioral interventions
Physical-activity support
Sleep and stress management
Treatment of weight-promoting medical conditions
Changes to weight-promoting medications when appropriate
Anti-obesity medication (scheduled 10/05/2026)
Endoscopic procedures
Metabolic and bariatric surgery
Combinations of these treatments
Monitoring without starting a new intervention

Different treatments provide different average benefits, risks, costs, burdens, and levels of long-term support.
The “best” option is not necessarily the treatment that produces the greatest average weight loss. It is the medically appropriate option that best fits the patient’s health risks, priorities, resources, and preferences.

What Shared Decision-Making Is

Shared decision-making involves several steps:

Recognizing that a decision needs to be made
Explaining the reasonable options
Discussing expected benefits, risks, and uncertainties
Understanding what matters to the patient
Reaching a decision together
Revisiting the decision as circumstances change

The process may happen during one appointment or over several conversations.
A patient does not have to make an immediate decision simply because options were presented.

What Shared Decision-Making Is Not

Shared decision-making is not:

A clinician making the decision and asking the patient to agree
A patient demanding a medically unsafe treatment
Giving a patient a medication list without explanation
Requiring weight loss before offering treatment
Using fear or shame to obtain consent
Steering every patient toward the clinician’s preferred product
Presenting only the options covered by one pharmacy
Hiding lower-cost alternatives
Promising a particular amount of weight loss
Transferring all responsibility to the patient

The provider remains responsible for identifying contraindications, explaining uncertainty, and declining treatment that is unsafe or medically inappropriate.
The patient retains the right to decline, pause, or reconsider treatment.

Informed Consent Is Necessary but Not Sufficient

Informed consent requires disclosure of relevant benefits, risks, alternatives, and uncertainties. Shared decision-making goes further by exploring how those facts apply to the individual patient.
For example, two patients may be medically eligible for the same weekly injectable medication.
One may prioritize:

The greatest expected weight reduction
Reduced cardiovascular risk
Fewer daily treatment decisions
Long-term appetite control

The other may prioritize:

Avoiding injections
Lower monthly cost
Pregnancy planning
Avoiding gastrointestinal effects
Using medication only for a limited period

The medical evidence is the same, but the appropriate decision may differ.

The Conversation Should Begin With the Patient’s Goals

A clinician should not assume that every patient’s main goal is reaching the lowest possible weight.
Possible goals include:

Preventing type 2 diabetes
Improving blood pressure
Reducing food noise
Improving sleep apnea
Relieving joint pain
Improving mobility
Supporting fertility
Improving fatty liver disease
Reducing cardiovascular risk
Maintaining current weight (scheduled 10/02/2026)
Preventing weight regain
Preparing for surgery
Improving energy or quality of life
Feeling more comfortable in clothing
Preserving muscle and physical function (scheduled 10/22/2026)

Some goals may be achieved with relatively modest weight reduction. Others may require a treatment with greater average efficacy.
Goals can also change over time.

Weight Is Not the Only Outcome

Obesity treatment should consider outcomes beyond the number on the scale.
Relevant measures may include:

Waist circumference
Blood pressure
Glucose and A1C
Lipids
Liver health
Sleep-apnea severity
Mobility
Physical function
Hunger and cravings
Binge-eating symptoms
Medication burden
Quality of life
Muscle preservation
Ability to maintain progress

A treatment may be clinically beneficial even if weight loss is slower than expected. Conversely, rapid weight loss is not automatically successful if it causes malnutrition, severe side effects, muscle loss, or worsening eating-disorder symptoms.

Previous Treatment Experiences Matter

A useful conversation includes what the patient has already tried.
This may include:

Commercial weight-loss programs
Calorie tracking
Low-carbohydrate or low-fat diets
Fasting
Exercise programs
Prescription medication
Compounded medication
FDA-approved obesity medication
Bariatric surgery
Therapy for binge eating
Previous weight loss and regain

The purpose is not to determine whether the patient tried hard enough. It is to learn:

What helped
What was unsustainable
What caused side effects
What the patient disliked
What created shame or disordered eating
What might be worth trying differently

Repeated treatment failure may reflect an ineffective treatment—not an unmotivated patient.

Choosing an Antiobesity Medication

Medication selection should be based on more than which product is most popular. (scheduled 10/05/2026)
Important considerations include:

Weight-related complications
Expected treatment benefit
Cardiovascular disease
Diabetes or prediabetes
Sleep apnea
Liver disease
Blood pressure
Heart rate
Kidney and gallbladder history
Seizure history
Eating-disorder history
Mental-health conditions
Current medications
Pregnancy potential and plans
Route and frequency of administration
Side-effect tolerance
Cost and insurance coverage
Medication availability
Long-term affordability

A medication with greater average efficacy may still be a poor choice if the patient cannot tolerate, access, or continue it.
A less expensive medication may be reasonable for one patient and medically unsuitable for another.

Expected Benefits Should Be Presented Honestly

Clinical-trial averages do not predict exactly what one patient will experience.
Patients should understand that:

Some people lose more than the average.
Some lose less.
Some stop because of side effects.
Response may take time.
Weight loss is rarely linear.
Plateaus are expected.
Maximum doses are not necessary for everyone.
Not every medication works for every person.
Switching or combining treatments may eventually be considered.
Long-term maintenance often requires continued treatment.

Advertising often emphasizes the highest or average weight reduction while giving less attention to discontinuation, variability, cost, and long-term maintenance.
Shared decision-making requires the entire picture.

Risks Should Be Explained Without Using Fear

A long list of possible adverse effects is not automatically useful. Patients need help understanding:

Which effects are common
Which are uncommon but serious
Which risks apply specifically to them
Which symptoms require evaluation
What monitoring may be needed
Whether risk changes with dose
Whether the effect is reversible
What alternative treatments carry different risks

Rare risks should not be hidden. They should also not be presented as expected outcomes.
The goal is informed choice—not fear-based consent.

Cost Is a Clinical Issue

A treatment is not sustainable if a patient cannot reliably afford it.
Cost discussions may include:

Insurance coverage
Deductibles and copays
Prior-authorization requirements
Manufacturer programs (scheduled 09/26/2026)
Cash-pay prices
Pharmacy costs
Laboratory expenses
Follow-up fees
The likelihood that pricing may change
What happens if coverage is lost (scheduled 09/27/2026)

Patients deserve to know whether the proposed plan is likely to require ongoing treatment and what alternatives exist if cost becomes a barrier.
Recommending an unaffordable medication without discussing realistic access is not meaningful shared decision-making.

Compounded and FDA-Approved Medications Require Clear Language

When compounded medication is discussed, patients should understand that it is not the same as an FDA-approved brand product.
The conversation should address:

Why compounded medication is being considered
Whether an FDA-approved option is available
Differences in regulatory review
The dispensing pharmacy
Formulation and concentration
Dosing and measurement requirements
Storage and beyond-use dating
Cost
Known uncertainties
What happens if access changes

Calling a compounded medication “generic Wegovy” or “generic Zepbound” is inaccurate. True generic versions are approved through a separate FDA process.
Patients cannot make an informed choice if the medication type is obscured.

Surgery Should Be Discussed as a Valid Option

Metabolic and bariatric surgery should not be framed as failure or as a last-minute punishment for having severe obesity.
For eligible patients, it can provide:

Greater average weight reduction
Durable improvement in some metabolic conditions
Diabetes remission in some patients
Reduced medication burden
Improved quality of life
Reduced long-term health risks

Surgery also involves:

Operative risk
Permanent anatomical changes for many procedures
Nutritional supplementation
Long-term monitoring
Potential gastrointestinal complications
Possible weight recurrence
Body-image and relationship changes
Additional procedures in some cases

A patient deserves a balanced discussion, not being pushed toward surgery or prevented from considering it.

Choosing a Bariatric Procedure

When more than one procedure is appropriate, shared decision-making may consider:

Expected weight reduction
Reflux
Diabetes
Medication absorption
Nutritional risks
Previous abdominal surgery
Surgical risk
Pregnancy plans
Long-term follow-up
The patient’s tolerance for anatomical change
The possibility of revision

The surgeon provides recommendations and identifies procedures that are unsafe or unsuitable. The patient’s preferences remain part of the final decision.

Choosing Not to Start Treatment Is Still a Decision

A patient may decide to:

Continue current treatment
Delay medication
Seek another opinion
Address another medical issue first
Begin with a lower-intensity option
Decline weight-focused treatment
Focus on weight maintenance
Reconsider later

Declining one option is not the same as declining all healthcare.
A clinician should not withdraw respectful care because a patient does not choose the recommended treatment.

Pregnancy Plans Can Change the Decision

Pregnancy potential and timing are especially important because antiobesity medications are generally not used during pregnancy, and some require discontinuation before conception.
Shared decision-making should include:

Whether pregnancy is possible
Current contraception
Near-term pregnancy plans
Fertility treatment
PCOS-related fertility changes
What happens if pregnancy occurs
How treatment may affect oral contraceptive reliability
Postpartum and breastfeeding considerations

The purpose is not to control reproductive decisions. It is to ensure that the obesity plan is compatible with the patient’s goals.

Mental Health and Eating Disorders Matter

Obesity care should include attention to:

Depression
Anxiety
PTSD
Binge-eating disorder
Bulimia nervosa
Restrictive eating
Substance use
Suicidal thoughts
Previous trauma

These conditions do not automatically exclude a patient from obesity treatment. They may change which treatment is appropriate and what support or monitoring is needed.
A patient should not be required to disclose trauma details to qualify for respectful care.

The Patient’s Preferred Role Can Vary

Not every patient wants to compare every treatment independently.
Some patients prefer:

A detailed review of all options
Two or three clinician-selected choices
A clear recommendation with supporting reasons
Time to research before deciding
A highly collaborative discussion
Greater clinician direction

Shared decision-making does not require the clinician to become passive. A patient may reasonably ask, “Given what you know about me, what would you recommend?”
The clinician should provide a recommendation while making clear that the final choice remains collaborative.

“What Would You Do?” Is Not the Most Important Question

A clinician’s personal choice may be influenced by different finances, health history, risk tolerance, family plans, and treatment priorities.
A more useful question is:
“Based on my health history and goals, why do you think this option fits me better than the alternatives?”
The answer should contain clinical reasoning—not simply personal preference.

Decisions Should Be Revisited

A treatment decision is not permanent simply because consent was signed.
Reassessment may be appropriate when:

Side effects become difficult
Hunger remains poorly controlled
Weight-related complications improve or worsen
Pregnancy plans change
Cost or insurance changes
Medication becomes unavailable
Treatment goals change
An eating disorder emerges
The patient reaches maintenance
Weight recurrence occurs

Continuing, adjusting, switching, combining, or stopping treatment may require renewed discussion.

What Patients Should Understand Before Starting

A meaningful conversation should help the patient understand:

What condition is being treated
The realistic goals of treatment
Available options
Why a particular option is recommended
Expected benefits
Common and serious risks
Important alternatives
Monitoring requirements
Expected cost
Whether treatment is likely to be long term
What may happen after discontinuation
How success will be evaluated
When the decision will be reviewed

If the patient cannot explain the basic plan afterward, the communication process may not have been adequate.

The Provider Is a Guide, Not the Owner of the Patient’s Health

The clinician’s role is to:

Present accurate information
Identify risks
Correct misinformation
Recommend appropriate options
Respect patient priorities
Monitor safety
Adjust treatment when needed
Decline unsafe prescribing
Remain available when preferences change

The patient lives with the consequences of the decision. It is their health, body, finances, and daily life.
Shared decision-making recognizes that medical expertise and lived experience are both necessary.

The Bottom Line

Shared decision-making in obesity treatment means combining the best available evidence with the patient’s goals, values, preferences, health history, and real-world access.
It does not mean the patient must choose without guidance, and it does not require a clinician to provide unsafe treatment. It means recommendations are explained, alternatives are discussed honestly, and the patient is treated as the final authority on what matters most in their own life.
The right obesity treatment is not simply the most powerful option. It is an effective, medically appropriate, acceptable, and sustainable plan that the patient understands and chooses.

Ready to Learn More About Medical Weight Management?

At Optima Vida Healthcare, weight-management evaluations consider health history, previous treatments, medication response, side effects, goals, and long-term needs. Treatment may include lifestyle support, laboratory evaluation, and medication when clinically appropriate.

Start Your Weight-Management Evaluation →

Visit www.ovhmed.com for more information.

The visit fee covers medical evaluation and related clinical services only. Medication, pharmacy, laboratory, and other third-party costs are separate unless specifically stated. A prescription is not guaranteed. Prescribing decisions are made by a licensed healthcare provider after clinical evaluation.

Medical Disclaimer

This article is for general educational purposes only. It does not provide individualized medical advice, diagnosis, treatment recommendations, insurance advice, or informed consent and does not establish a provider-patient relationship. Treatment decisions require evaluation by a qualified healthcare professional.

References

shared decision-making in obesity treatment
obesity treatment choices, choosing weight-loss medication, patient-centered obesity care, informed consent in obesity care, shared treatment decisions
Shared decision-making combines medical evidence with a patient’s goals, preferences, experiences, and access. Learn how this process supports informed obesity treatment choices.